Research Article
BibTex RIS Cite

Thrombopoietic factors

Year 1997, Volume: 10 Issue: 1, 48 - 51, 01.01.1997

Abstract

Over the past two decades, there have been major advances in the therapy of malignancies. One of the major obstacies to the delivery of effective doses of chemotherapeutic agents is the hematopoietic toxicity associated with certain agents. Chemotherapy dose modification, administration of antibiotics and red cell and platelet transfusions have constituted the major means for coping with the hematologic side effects of cancer treatment. Despite the considerable success of these supportive care efforts, myelosuppression is still an important problem both for health care workers and patients. After the successful use of granulocyte colony stimulating factor (G-CSF) as prophylaxis against neutrophilic complications of chemotherapy, attention has shifted to thrombocytopenia and encouraged the clinical investigation of several agents with the ability to stimulate thrombocytosis.

Among the variety of thrombopoietic molecules, five agents have now been tested clinically. These are interleukin 1 (IL-1), IL-3, IL-4, IL-11 and IL-3 and GM- CSF fusion protein (PIXY321). Two other molecules IL-3 mimetic (SC55494) and thrombopoietin (TPO) are poised to enter clinical trials. Current information about these molecules are largely confined to toxicity data and very limited efficacy results from phase I investigations.

References

  • Smith JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a Phase I trial to patients with advanced malignancies. J Clin Oncol 1992,10:1141-1152.
Year 1997, Volume: 10 Issue: 1, 48 - 51, 01.01.1997

Abstract

References

  • Smith JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a Phase I trial to patients with advanced malignancies. J Clin Oncol 1992,10:1141-1152.
There are 1 citations in total.

Details

Subjects Clinical Sciences
Journal Section Review Makaleler
Authors

T. Fıratlı Tuğlular This is me

Publication Date January 1, 1997
Published in Issue Year 1997 Volume: 10 Issue: 1

Cite

APA Fıratlı Tuğlular, T. (1997). Thrombopoietic factors. Marmara Medical Journal, 10(1), 48-51.
AMA Fıratlı Tuğlular T. Thrombopoietic factors. Marmara Med J. January 1997;10(1):48-51.
Chicago Fıratlı Tuğlular, T. “Thrombopoietic Factors”. Marmara Medical Journal 10, no. 1 (January 1997): 48-51.
EndNote Fıratlı Tuğlular T (January 1, 1997) Thrombopoietic factors. Marmara Medical Journal 10 1 48–51.
IEEE T. Fıratlı Tuğlular, “Thrombopoietic factors”, Marmara Med J, vol. 10, no. 1, pp. 48–51, 1997.
ISNAD Fıratlı Tuğlular, T. “Thrombopoietic Factors”. Marmara Medical Journal 10/1 (January 1997), 48-51.
JAMA Fıratlı Tuğlular T. Thrombopoietic factors. Marmara Med J. 1997;10:48–51.
MLA Fıratlı Tuğlular, T. “Thrombopoietic Factors”. Marmara Medical Journal, vol. 10, no. 1, 1997, pp. 48-51.
Vancouver Fıratlı Tuğlular T. Thrombopoietic factors. Marmara Med J. 1997;10(1):48-51.